InvestSMART

Aroa Biosurgery Limited (ASX: ARX) - Announcements

- Current share price for ARX : $0.530

ASX company news and announcements for Aroa Biosurgery Limited (ARX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Aroa Biosurgery Limited (ARX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Aroa Biosurgery Limited (ARX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Aroa Biosurgery Limited (ARX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$183 Section 708A Cleansing Statement 11 Jun 2021 3:43PM $1.083 $0.530 fallen by 51.04%
$183 FY21 Full Year Results Presentation 25 May 2021 9:09AM $1.180 $0.530 fallen by 55.08%
$183 Preliminary Final Report 25 May 2021 9:09AM $1.180 $0.530 fallen by 55.08%
$183 Notice of AGM Date and Director Nomination Closing Date 24 May 2021 2:01PM $1.170 $0.530 fallen by 54.70%
$183 Aroa Biosurgery Full Year Results Webinar 21 May 2021 9:56AM $1.130 $0.530 fallen by 53.10%
$183 Appendix 3G 4 May 2021 10:01AM $1.140 $0.530 fallen by 53.51%
$183 Quarterly Results Webinar 28 Apr 2021 8:52AM $1.160 $0.530 fallen by 54.31%
$183 March Quarterly Report and Appendix 4C 28 Apr 2021 8:51AM $1.160 $0.530 fallen by 54.31%
$183 Change of Registered Office 21 Apr 2021 1:08PM $1.140 $0.530 fallen by 53.51%
$183 Aroa secures FDA clearance for new product 6 Apr 2021 9:00AM $1.140 $0.530 fallen by 53.51%
$183 Aroa to present at NWR Virtual Investor Conference 17 Mar 2021 3:39PM $1.200 $0.530 fallen by 55.83%
$183 S&P DJI Announces March 2021 Quarterly Rebalance 12 Mar 2021 5:02PM $1.200 $0.530 fallen by 55.83%
$183 Change of Director's Interest Notice - JD 23 Feb 2021 3:05PM $1.235 $0.530 fallen by 57.09%
$183 Pilot study indicates benefits of Myriad in surgical reconst 16 Feb 2021 10:00AM $1.200 $0.530 fallen by 55.83%
$183 Aroa to further expand dedicated US sales team 2 Feb 2021 8:56AM $1.080 $0.530 fallen by 50.93%
$183 Change in substantial holding 28 Jan 2021 3:06PM $1.120 $0.530 fallen by 52.68%
$183 December Quarterly Report and Appendix 4C 27 Jan 2021 9:19AM $1.040 $0.530 fallen by 49.04%
$183 Aroa Biosurgery December 2020 Quarterly Webinar 27 Jan 2021 9:16AM $1.040 $0.530 fallen by 49.04%
$183 Release of Shares from Voluntary Escrow 18 Jan 2021 8:29AM $1.115 $0.530 fallen by 52.47%
$183 New Study Shows Myriad Efficacy in Exposed Vital Structures 16 Dec 2020 9:05AM $1.100 $0.530 fallen by 51.82%
$183 Change of Director's Interest Notice - JD 10 Dec 2020 12:23PM $1.230 $0.530 fallen by 56.91%
$183 Section 708A Cleansing Statement and Appendix 2A 10 Dec 2020 12:19PM $1.230 $0.530 fallen by 56.91%
$183 Indian Regulatory Approval received for three Aroa products 9 Dec 2020 8:26AM $1.205 $0.530 fallen by 56.02%
$183 Aroa Half Year Results Webinar 26 Nov 2020 8:25AM $1.315 $0.530 fallen by 59.70%
$183 Appendix 4D and Half Year Report 26 Nov 2020 8:24AM $1.315 $0.530 fallen by 59.70%

301 - 325 of 765 results

Page 13 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.